Company > Profile

Scott Byrd


Scott is the Chief Executive Officer at Sudo Biosciences, and director of Algo Therapeutix. He has more than 20 years of experience in the pharmaceutical industry. He is an Entrepreneur-in-Residence at Frazier Lifesciences. Scott was formerly the Chief Executive Officer of Outpost Medicine. Prior to this he was Chief Operating Officer of Acacia Pharma. Before this, he was the Chief Commercial Officer & Senior Vice President of Cadence Pharmaceuticals, Inc. from June 2009 until its acquisition by Mallinckrodt Pharmaceuticals plc in March 2014. In this role, Scott was responsible for all of Cadence’s commercial activities, in particular building and leading the group’s US sales and marketing infrastructure for Ofirmev®, a post-operative pain control product promoted to anesthesiologist and surgical teams. Previously, Scott served in a variety of US and global roles in sales, marketing, finance, manufacturing and strategic planning at Eli Lilly and Company starting in January 1992. Scott holds a BS in mechanical engineering from Bradley University and an MBA from Harvard Business School.

Scott joined the Board of Acacia Pharma Group plc in December 2017 and is a member of the Remuneration Committee. Scott was appointed Chairman of Acacia Pharma Group plc following the 2020 AGM

< back to Board